Christopher Geven

Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis

Christopher Geven, Andreas Bergmann, Matthijs Kox et al. · Shock · 2018 · 81 citations

Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis

Christopher Geven, Esther Peters, Mathias Schroedter et al. · Shock · 2018 · 47 citations

A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

Christopher Geven, Alice Blet, Matthijs Kox et al. · BMJ Open · 2019 · 46 citations · Full text

Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first‐in‐human study and during experimental human endotoxaemia in healthy subjects

Christopher Geven, Dirk van Lier, Alice Blet et al. · British Journal of Clinical Pharmacology · 2018 · 44 citations · Full text

Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats

Alice Blet, Benjamin Deniau, Christopher Geven et al. · Intensive Care Medicine Experimental · 2019 · 29 citations · Full text